Right Patient-Right Drug-Right Time-95651_slide_ppt

《Right Patient-Right Drug-Right Time-95651_slide_ppt》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、RightDrug,RightPatient,RightTimePresentedByHowardWestat2014ASCOAnnualMeetingCombinedOSAnalysis:LUX-Lung3,LUX-Lung6:KeyFindingsPresentedByHowardWestat2014ASCOAnnualMeetingDifferencesinEfficacyofGefitinib/Erlotinib:Exon19Delvs.L858RPresentedByHowardWestat2014ASCOAnnualMeeting

2、IsOSwithAfatinibinLUX-Lung3/6SuperiortoThatofOtherEGFRTKIs?PresentedByHowardWestat2014ASCOAnnualMeetingCouldLowCrossover
ExplaintheDifference?PresentedByHowardWestat2014ASCOAnnualMeetingMultipleShotsonGoalPresentedByHowardWestat2014ASCOAnnualMeetingRelevantComparisonfor

3、Afatinib
in2014istoOtherEGFRTKIsPresentedByHowardWestat2014ASCOAnnualMeetingButwhataboutanEGFRTKI/bevacizumabcombination?PresentedByHowardWestat2014ASCOAnnualMeetingErlotinib+/-BevacizumabasSecond-LineTherapy(BeTa):SubgroupAnalysisPresentedByHowardWestat2014ASCOAnnualMe

4、etingErlotinib+/-BevacizumabasMaintenanceTherapy(ATLAS):ClinicalSubgroupsPresentedByHowardWestat2014ASCOAnnualMeetingEGFRRegulatesVEGFin
EGFRMutantCellLinesPresentedByHowardWestat2014ASCOAnnualMeetingJO25587PFSinContextofOtherTrials
inEGFRMutation-PositiveNSCLCPrese

5、ntedByHowardWestat2014ASCOAnnualMeetingKato:PFSbyEGFRmutationtypePresentedByHowardWestat2014ASCOAnnualMeetingToxicitywithErlotinib/Bevacizumab
onJO25587PresentedByHowardWestat2014ASCOAnnualMeetingCostConsiderationswith
Erlotinib/BevCombinationPresentedByHowardWestat

6、2014ASCOAnnualMeetingIsErlotinib/BevOptimalStrategyforEGFRMutation-PositiveNSCLC?PresentedByHowardWestat2014ASCOAnnualMeetingCeritinib:HighlyActiveTreatment
OptionforALK-PositiveNSCLCPresentedByHowardWestat2014ASCOAnnualMeetingToxicityChallengeswithCeritinibPresentedByH

7、owardWestat2014ASCOAnnualMeetingCeritinibFDAApprovedApril29,2014PresentedByHowardWestat2014ASCOAnnualMeetingTimingofCeritinib?PresentedByHowardWestat2014ASCOAnnualMeetingConclusions:BigEffectsShouldn’tRequireBigTrialsPresentedByHowardWestat2014ASCOAnnualMeeting